摘要
目的探究齐拉西酮联合氯氮平治疗难治性精神分裂症患者的临床效果。方法选取2019年2月至2022年2月上饶市第三人民医院横峰分院精神科收治的80例难治性精神分裂症患者作为研究对象,采用随机抽签法分为对照组与观察组,各40例。对照组给予单独氨氯平治疗,观察组给予齐拉西酮联合氯氮平治疗。比较两组临床疗效、实验室检查结果、阴性及阳性症状改善情况、认知功能、用药安全性。结果观察组治疗总有效率为95.00%,高于对照组的80.00%,差异有统计学意义(P<0.05)。用药3个月后,两组神经元特异性烯醇化酶(neuron specific enolase,NSE)、白细胞介素-1β(interleukin-1β,IL-1β)水平均低于用药前,胶质源性神经营养因子(glial cell line-derived neurotrophic factor,GDNF)水平高于用药前,且观察组NSE、IL-1β水平均低于对照组,GDNF水平高于对照组,差异有统计学意义(P<0.05)。用药3个月后,两组阳性与阴性症状量表(positive and negative syndrome scale,PANSS)评分均低于用药前,且观察组低于对照组,差异有统计学意义(P<0.05)。用药3个月后,两组连线测验(trail making test,TMT)评分均低于用药前,且观察组低于对照组,差异有统计学意义(P<0.05)。用药期间,两组不良反应发生率比较差异无统计学意义。结论齐拉西酮联合氯氮平方案治疗难治性精神分裂症患者的疗效显著,可缓解患者阴性及阳性症状,改善认知功能,安全性较高,值得临床推广应用。
Objective To investigate the clinical efficacy of ziprasidone combined with clozapine in the treatment of refractory schizophrenia patients.Methods 80 patients with refractory schizophrenia admitted to the Hengfeng Branch of the Third People's Hospital of Shangrao City from February 2019 to February 2022 were selected as the study subjects,and they were randomly divided into the control group and the observation group,with 40 cases in each group.The control group was treated with amlodipine alone,while the observation group was treated with ziprasidone combined with clozapine.The clinical efficacy,laboratory results,improvement of negative and positive symptoms,cognitive function and drug safety were compared between the two groups.Results The total effective rate in the observation group was 95.00%,which was higher than 80.00%in the control group,and the difference was statistically significant(P<0.05).After 3 months of medication,the levels of neuron specific enolase(NSE)and interleukin-1β(IL-1β)of the two groups were lower than before medication,while the level of glial derived neurotrophic factor(GDNF)was higher than before medication,and the levels of NSE and IL-1βin the observation group were lower than those in the control group,and the level of GDNF was higher than that in the control group,and the differences were statistically significant(P<0.05).After 3 months of medication,the positive and negative syndrome scale(PANSS)of the two groups were lower than before medication,and the observation group was lower than the control group,and the differences were statistically significant(P<0.05).After 3 months of medication,the trail making test(TMT)scores of the two groups were lower than before medication,and the observation group was lower than the control group,and the differences were statistically significant(P<0.05).During the medication period,there was no statistically significant difference in the incidence of adverse reactions between the two groups.Conclusion Ziprasidone combined with clozapine i
作者
孔凡佳
汪斌
杨春英
KONG Fanjia;WANG Bin;YANG Chunying(Department ofWomen's,Hengfeng Branch of Shangrao Third People's Hospital,Shangrao,Jiangxi,334300,China;Department of Men's,Hengfeng Branch of Shangrao Third People's Hospital,Shangrao,Jiangxi,334300,China)
出处
《当代医学》
2024年第17期104-108,共5页
Contemporary Medicine
